Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
ID: 356747Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)." This initiative invites applications that focus on the neurological and mental health manifestations associated with chronic illnesses resulting from infections, particularly the post-acute sequelae of COVID-19 (Neuro-PASC) and other conditions with potential infectious triggers. The funding aims to advance research into the mechanisms underlying these conditions, including neuroinflammation and brain dysfunction, with an emphasis on stakeholder engagement from underserved populations. Applications are due by November 6, 2025, with budgets capped at $500,000 annually and project durations of up to five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institutes of Health (NIH), through the Department of Health and Human Services, has announced a funding opportunity titled "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)." The initiative invites applications focused on neurological and mental health manifestations linked to chronic illnesses resulting from infections, particularly post-acute sequelae of COVID-19 (Neuro-PASC) and other conditions with potential infectious triggers. The announcement emphasizes research examining mechanisms underlying such conditions, including neuroinflammation, brain dysfunction, and possible shared pathophysiological pathways. Applications are encouraged to include plans for stakeholder engagement, especially from underserved populations significantly impacted by these illnesses. The funding mechanism permits both new and resubmission applications with budgets below $500,000 annually and a project duration of up to five years. Key dates include the opening of applications on January 5, 2025, with a final submission deadline of November 6, 2025. The document details eligibility criteria for applicants, funding restrictions, and the review process for assessing the scientific merit of submissions, emphasizing the importance of understanding the overlap between various infection-associated chronic illnesses in advancing therapeutic development.
    Similar Opportunities
    Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses" (R21 - Clinical Trial Optional) aimed at supporting research into the neurological and mental health outcomes associated with chronic illnesses linked to infections, including the post-acute sequelae of COVID-19 (Neuro-PASC). The initiative encourages applications that investigate the mechanisms underlying these conditions, with a particular interest in studies that explore common pathophysiologies across various infection-associated chronic illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and postural orthostatic tachycardia syndrome (POTS). Eligible applicants include a wide range of organizations, including higher education institutions and nonprofits, with a maximum funding amount of $275,000 available for a two-year project period. Applications are due by 5:00 PM local time on November 16, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at enhancing the understanding of the neurological effects associated with infection-related chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This initiative encourages research projects that explore the neurological and psychiatric manifestations of these illnesses, with a particular interest in studies that may identify common neuropsychiatric mechanisms across multiple conditions, although applications focusing on individual illnesses are also welcome. The NOFO is anticipated to be released in Fall 2024, with applications due in Winter 2025, and will utilize the R21 grant mechanism. Interested applicants should prepare for a project start date expected in December 2025, with further details to be outlined in the forthcoming announcement.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)" aimed at researching the mechanisms of T-cell involvement in HIV-related central nervous system (CNS) issues. This initiative seeks to develop therapeutic strategies that address T-cell neuro-invasion and HIV-associated neuroinflammation, with a focus on innovative and multidisciplinary approaches utilizing advanced technologies. Approximately $5.5 million is available for this research, with applications opening on February 17, 2025, and a submission deadline of March 18, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for prospective observational comparative effectiveness research (CER) in clinical neurosciences under the funding opportunity number PAR-25-048. This initiative aims to support investigator-initiated studies that evaluate the effectiveness of existing interventions, treatments, or diagnostic approaches for neurological disorders in real-world settings. The funding mechanism is a cooperative agreement divided into two phases: a 2-year UG3 planning phase and a 5-year UH3 implementation phase, contingent on meeting scientific milestones. Applications are encouraged from a diverse range of institutions, particularly those focusing on underrepresented populations and diseases. Key deadlines include an application due date of February 19, 2025, and a funding expiration on September 8, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for prospective observational comparative effectiveness research (CER) in clinical neurosciences, specifically through the National Institute of Neurological Disorders and Stroke (NINDS). This initiative aims to encourage grant applications that investigate preventive strategies, diagnostic approaches, and various interventions, including drugs, devices, and therapies, that align with NINDS's mission. The funding mechanism follows a UG3/UH3 cooperative agreement structure, starting with a 2-year planning phase (UG3) that may transition into a 5-year observational study phase (UH3) upon meeting specific milestones. Interested applicants, including a diverse range of organizations, must submit their applications by May 7, 2025, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Studies of Mental Illness (Collaborative R01)" aimed at supporting multidisciplinary clinical studies focused on mental health, particularly in areas such as genetics, biomarkers, and various mental illnesses. This initiative encourages collaboration across multiple sites to enhance sample sizes and diversity in participant recruitment, specifically targeting health disparity populations. The program allows for a project period of up to five years with no explicit budget limits, although proposed budgets must be well justified. Interested applicants, including various educational and nonprofit institutions, should submit their applications by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed)" aimed at investigating the mechanisms by which T-cells contribute to HIV's neurological implications. This initiative seeks to enhance understanding of HIV's seeding and persistence in the central nervous system (CNS), as well as its associated neurological disorders, encouraging research that explores T-cell neuro-invasion and potential therapeutic strategies. The total funding available is $5.5 million, with individual budgets capped at $275,000 over a two-year period, and applications are encouraged from a diverse range of eligible organizations, including higher education institutions and non-profits. Interested applicants should note that the submission deadline is March 18, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for further details.
    Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), has announced a funding opportunity titled "Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes." This initiative aims to support research projects that evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting various age groups, with a focus on clinical trials that assess long-term recovery and treatment adherence. The funding opportunity is open to a diverse range of applicants, including higher education institutions and community-based organizations, with a maximum project period of five years. Interested parties should note that the application deadline is January 7, 2028, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-207.html.